Focused On-demand Library for Protein moonraker

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The focused library is created on demand with the latest virtual screening and parameter assessment technology, supported by the Receptor.AI drug discovery platform. This method is more effective than traditional methods and results in higher-quality compounds with better activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries.

Fig. 1. The sreening workflow of Receptor.AI

Utilising molecular simulations, our approach thoroughly examines a wide array of proteins, tracking their conformational changes individually and within complexes. Ensemble virtual screening enables us to address conformational flexibility, revealing essential binding sites at functional regions and allosteric locations. Our rigorous analysis guarantees that no potential mechanism of action is overlooked, aiming to uncover new therapeutic targets and lead compounds across diverse biological functions.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

Q2KHM9

UPID:

MOONR_HUMAN

Alternative names:

OFD1- and FOPNL-interacting protein

Alternative UPACC:

Q2KHM9; A8KA11; B7Z479; O94853; Q05D97; Q2KHN0; Q9UG45

Background:

Protein moonraker, also known as OFD1- and FOPNL-interacting protein, plays a crucial role in centriole duplication and is essential for proper cell division. It positively regulates CEP63 centrosomal localization and is necessary for WDR62 centrosomal localization, promoting CDK2's centrosomal presence. This protein may also be involved in cilium assembly, indicating its multifaceted role in cellular structure and function.

Therapeutic significance:

Protein moonraker's involvement in diseases such as Orofaciodigital syndrome 15, Joubert syndrome 38, and Short-rib thoracic dysplasia 21 without polydactyly highlights its potential as a target for therapeutic intervention. Understanding the role of Protein moonraker could open doors to potential therapeutic strategies, offering hope for patients suffering from these genetic disorders.